MEI Pharma responds to consent solicitation launched by Anson

MEI Pharma issued the following statement in response to the Consent Solicitation launched by Anson Advisors and Cable Car Capital on July 17 : “Anson and Cable Car have launched a process, called a consent solicitation, in an attempt to take control of the Company by removing MEI’s directors. The consent solicitation further seeks to have MEI repeal any amendment to our bylaws since February 22, 2023 and prevent any future amendment prior to completion of the consent solicitation. As we noted in our direct response back to Anson and Cable Car, MEI is incorporated in Delaware and their attempt to remove our Board of Directors without cause is not allowed under Delaware law. Moreover, the MEI Board has not made or proposed any modification of the bylaws to date, nor does it have any current intention to do so. ..The Company’s response to the consent solicitation from Anson and Cable Car is being filed on Form 8-K with the U.S. Securities and Exchange Commission on July 18,” said the MEI Pharma response.